18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
PyL, also known as [18F]DCFPyL, is a second-generation fluorinated prostate-specific membrane
antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher
detection of metastatic prostate lesions compared to standard imaging. Its ability to image
metastatic prostate cancer sites was comparable to 68Ga-PSMA with high tumor-to-background
ratios.Additionally, [18F] PyL demonstrated higher mean tumor-to-background ratios when using
kidney, spleen, or parotid as reference organs. However, the role of [18F] PyL in tumor
response to therapy has not been evaluated, specifically the potential to serve as a
predictive biomarker of response. Given the high cost of current therapeutic agents in mCRPC,
there is a need for an early response biomarker to stratify which patients will benefit from
therapy and which will not. This will also allow for earlier change in management of patients
who will not response to these therapies, potentially improving patient outcomes.